SUBCUTANEOUS DRUG ADMINISTRATION DEVICE

The integration of the cap with the patch layer and a position sensor in the device simplifies preparation and ensures safe, secure medication administration by preventing accidental needle exposure and ensuring proper device activation.

FR3142679B3Active Publication Date: 2024-11-22NUOVA OMPI SRL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
FR2023013414
Authority / Receiving Office
FR · FR
Patent Type
Utility models
Current Assignee / Owner
Priority Date
2022-12-01
Filing Date
2023-12-01
Publication Date
2024-11-22
Estimated Expiration
2033-12-01

AI Technical Summary

Technical Problem

Existing wearable medication administration devices have complex mechanisms for ensuring the cap is removed only when the device is ready for use and risk accidental needle exposure due to improper handling.

Method used

A device design where the cap is integrated with a protective patch layer, allowing simultaneous removal of the cap and patch layer before application, featuring a protective element that covers the needle until use and a position sensor to ensure safe operation.

Benefits of technology

Simplifies device preparation and ensures safe, secure administration by integrating the cap with the patch layer and using a position sensor to prevent accidental activation before use, enhancing patient safety and device usability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The invention relates to a device (1) for subcutaneous drug delivery, comprising a base surface (12) designed to face the patient's skin when the device (1) is applied to the patient's skin, and an injection needle configured to inject the drug into the patient when the device (1) is applied to the patient's skin. The injection needle is movable between a resting position in which the injection needle is fully contained within the device (1) and an injection position in which the injection needle protrudes at least partially from the device (1) through a through-hole formed in the base surface. The device (1) further comprises a patch (30) including an adhesive layer (31) integrally bonded to the base surface (12) and a protective layer (32) designed to be removed to fix the adhesive layer (31) to the patient's skin.A cap (40) is removably attached to the base surface (12) at the through-hole. In particular, the cap (40) is integrally attached to the protective layer (32) of the patch (30). Figure 2 for the abbreviation.
Need to check novelty before this filing date? Find Prior Art

Description

Title of the invention: DEVICE FOR SUBCUTANEOUS ADMINISTRATION OF A MEDICINE Technical field of the invention

[0001] The present invention relates to a device for subcutaneous administration of a drug.

[0002] In particular, the device of the present invention falls within the category of "infusion pumps" as defined by the FDA (US Food and Drug Administration) and relates, more particularly, to a device of the type that can be worn on oneself, that is to say configured to be applied to the body of a patient in order to allow the subcutaneous administration of a predetermined dose of medication. The application of the device to the patient's body is carried out by a user, for example a doctor or a nurse or the patient. Technical background

[0003] Examples of delivery devices of the type discussed above are described in EP 3439715B1 and WO 2020 / 128821A1.

[0004] In all wearable delivery devices, the drug is initially contained in a cartridge housed within the device and is transferred into the patient's body via a fluid path.

[0005] In the present application, the term "fluidic path" is used to designate any element or set of elements which is configured to be connected, at a first end thereof, to the cartridge housed inside the administration device and comprising, at an end thereof opposite the first end mentioned above, an injection needle intended to be inserted into the patient's body to allow the transfer of the medicament from the cartridge to the patient's body.

[0006] Typically, the cartridge comprises a cylindrical container, made of a plastic or glass material, a plunger slidable within the container to push the drug out of the container and a pierceable septum which ensures the sterility of the container until the administration of the therapy begins.

[0007] Typically, the fluid path includes a piercing needle configured to pierce the pierceable septum of the cartridge and a flexible tube that places the piercing needle in fluid communication with the injection needle.

[0008] In such devices, the cartridge container is kept closed by the pierceable septum until administration of the drug is required. When such administration is required, the piercing needle pierces the pierceable septum and opens the fluid path, allowing the drug to reach the patient by passing first through the piercing needle, then through the flexible tube and finally through the injection needle, due to the thrust exerted by the plunger on the medicine inside the container.

[0009] Obviously, the administration of the drug to the patient takes place after the insertion of the injection needle into the patient's body. Such insertion occurs following the activation of a displacement mechanism configured to move the injection needle between a rest position in which the injection needle is fully disposed within the device and an injection position in which the injection needle protrudes from the device through a specifically provided through-opening and penetrates the patient's skin. The displacement mechanism may also be configured to extract the injection needle from the patient's skin at the end of the administration of the therapy by bringing it back inside the device.

[0010] From WO 2015 / 187797A1 and WO 2021 / 252971A2, for example, devices are known which are provided with a cap applied to the device at the through opening and intended to be removed from the device before applying the device to the patient's skin.

[0011] Both in WO 2015 / 187797A1 and WO 2021 / 252971A2, solutions are provided to ensure that the cap is only removed from the device when the device is actually to be used for therapy delivery. In particular, WO 2015 / 187797A1 discloses the use of sensors signaling a possible removal of the cap before the intended time and a control device signaling when the cap is to be removed. WO 2021 / 252971A2 instead discloses the use of a locking mechanism that allows the removal of the cap only just before the device is applied to the patient's skin for therapy delivery.

[0012] The applicant observed that the solutions disclosed in the devices of the prior art documents mentioned above are complex.

[0013] The Applicant thus felt the need to provide a constructively simpler solution adapted both to allow the cap to be kept on the device when the device is not being used for administering therapy and to allow easy removal of the cap when the device is actually to be used for administering therapy, i.e. just before applying the device to the patient's skin.

[0014] The Applicant has observed that many wearable type devices have a patch on the surface intended to face the patient's skin when the device is in use. Such a patch comprises an adhesive layer covered by a protective layer. The latter is intended to be removed in order to expose the adhesive layer, so that the device can then be attached to the patient's skin through the adhesive layer mentioned above.

[0015] The Applicant has realized that an extremely easy way to meet the above-mentioned need is to combine the cap with the protective layer of the patch. Summary of the invention

[0016] The present invention therefore relates to a device for subcutaneous administration of a drug, comprising: - a base surface intended to face the skin of a patient when the device is applied to the patient's skin and comprising a through opening; - a patch comprising an adhesive layer and a protective layer, wherein the adhesive layer is integrally associated with the base surface and is intended to be fixed to the patient's skin upon removal of the protective layer; - an injection needle configured to inject the medicament into a patient when the device is applied to the patient's skin, the injection needle being movable between a rest position in which the injection needle is fully disposed within the device and an injection position in which the injection needle protrudes at least partially from the device through said through opening; - a cap removably associated with said base surface at said through opening; wherein the cap is integrally associated with said protective layer.

[0017] In the device of the invention, it is possible to remove the cap only by removing the protective layer from the patch. Since the latter is removed just before applying the device to the patient's skin for administering the therapy, the cap remains applied to the device until the time when the device is actually to be used.

[0018] In addition, the operation of preparing the device for use is very simple. In fact, in a single action, the patient removes the protective layer of the patch and the cap, exposing the adhesive layer of the patch.

[0019] Preferred features of the device of the invention are described below. Each of these features may be provided individually or in combination with the others.

[0020] Preferably, the cap comprises a collar associated in one piece with a part of the protective layer by interposition of a double-sided adhesive element. The latter makes it possible to firmly bond the cap to the protective layer, making it de facto integral with the latter.

[0021] Preferably, the cap is made of a rigid material.

[0022] In preferred embodiments, the device further comprises an element protective element arranged around said through opening and movable between a first operating position in which the protective element projects from the device and a second operating position in which the protective element does not project from the device. This protective element makes it possible to protect the patient against accidental contact with the tip of the injection needle when the device is not applied to the patient's skin, if the injection needle is outside the device.

[0023] Preferably, it is provided that the protective element is in the first operating position before applying the device to the patient's skin and surrounds the tip of the injection needle in the event that the latter, for any reason, is outside the device. In fact, although it is provided that before removing the device from the patient's skin, the injection needle is brought back into the device, it cannot be excluded that following accidental or voluntary removal of the device from the patient's skin, the injection needle ends up outside the device, with the risk for the patient to be pricked.

[0024] Preferably, the device further comprises an elastic element associated with the protective element and configured to exert on said protective element a pushing action which is suitable for maintaining the protective element in the first operating position before removing the protective layer. Thus, in its initial configuration, the protective element projects from the device and is free to move from the outside to the inside of the device.

[0025] Preferably, the cap is configured to accommodate the protective element, preferably with clearance, before removing the protective layer. The cap thus prevents access to the protective element when the device is not in use for administering therapy, i.e., before applying the device to the patient's skin.

[0026] Preferably, the device comprises a flexible sleeve associated in a watertight manner with the device around said through opening and associated in one piece with the protective element.

[0027] By being associated in one piece with the protective element, the flexible sleeve moves with the protective element between the first operating position mentioned above in which the flexible sleeve and the protective element extend outside the device and the second operating position mentioned above in which the flexible sleeve and the protective element are housed inside the device. Therefore, by associating the flexible sleeve with the device around the protective element in a watertight manner, the impermeability of the device and the sealing also against powders at the through opening through which the injection needle exits for the administration of therapy.

[0028] Preferably, the protective element comprises a base provided with a through hole to allow the passage of the injection needle during movement of the injection needle between the rest position and the injection position.

[0029] Preferably, said base comprises a raised edge defining in the protective element a recess which houses the tip of the injection needle both when the protective element is in the second operating position and the injection needle is in the rest position and when the protective element is in the first operating position and the injection needle is in the injection position. The raised edge surrounds the tip of the injection needle and prevents the user from coming into contact with the tip if the injection needle is outside the device and the device is not applied to the patient's skin.

[0030] Preferably, the flexible sleeve is associated in one piece with said base.

[0031] Preferably, the flexible sleeve is defined by a membrane having a surface interior associated in one piece with the exterior surface of said base.

[0032] Preferably, the membrane has the shape of a bellows.

[0033] Preferably, the membrane has a substantially conical or frustoconical shape. In this way, the membrane can be telescopically folded inside the device when the device is applied to the patient's skin, thus occupying an extremely limited space, to the benefit of the compactness of the device.

[0034] Preferably, the membrane and the cap have a frustoconical shape.

[0035] Preferably, the flexible sleeve has a base surface integrally associated with the base of the protective element.

[0036] Preferably, said base surface covers the through hole of the base of the protective element and can be pierced by the injection needle when the injection needle passes from the rest position to the injection position. In this case, the flexible sleeve continuously covers the protective element also covering the through hole of the base of the protective element and it is the injection needle itself which pierces the base surface of the flexible sleeve when it emerges from the protective element and, consequently, from the flexible sleeve.

[0037] In preferred embodiments thereof, the device further comprises a position sensor configured to detect contact of the device with the patient's skin. By means of the above-mentioned sensor, it is ensured that the device cannot be put into operation before being applied to the patient's body or, in other words, the device can only be put into operation when it is actually in the condition to administer the medicament. This is particularly advantageous, since the medicaments used in these devices are typically very expensive and, in order to ensure patient safety, the device is considered to have been used im immediately after its introduction, whether the drug is then actually administered to the patient or whether such administration is successful.

[0038] Preferably, the position sensor comprises a magnet integrally associated with the protective element and a Hall effect sensor arranged in the device in proximity to the magnet. In this way, the detection of contact between the device and the patient's body takes place due to the movement of the protective element from the outside to the inside of the device as soon as the device is applied to the patient's body. In fact, this movement causes the magnet to approach the Hall effect sensor. Housing the protective element inside the cap becomes in this case particularly advantageous because it prevents the patient from voluntarily or accidentally moving the protective element when the device is not applied to the patient's skin, thus limiting the risks of putting the device into operation before its application to the patient's body.

[0039] Preferably, the magnet is associated in one piece with said base. Brief description of the figures

[0040] Other features and advantages of the present invention will become clearer upon reading the following detailed description of preferred embodiments thereof, made with reference to the accompanying drawings and given for informational and non-limiting purposes. In these drawings:

[0041] [Fig.l] - [Fig.l] is a perspective top view of a device according to the present invention without a patch;

[0042] [Fig.2] - [Fig.2] is a perspective bottom view of the device of [Fig.l] provided with a patch;

[0043] [Fig.3] - [Fig.3] is a perspective bottom view of the device of [Fig.l] after removing the protective layer from the patch;

[0044] [Fig.4] - [Fig.4] is a perspective sectional view of the device of [Fig.l] before being applied to the patient's skin;

[0045] [Fig.5] - [Fig.5] is a perspective sectional view of the device of [Fig.l] when applied to the patient's skin. Detailed description of the invention

[0046] In the attached figures, a device according to the present invention is indicated by the reference numeral 1.

[0047] The device 1 comprises an administration module 10 comprising a base surface 12 intended to be applied to the skin of a patient and a control module 20 intended to control the operation of the device 1. In particular, the control module 20 comprises a control unit (not visible), generally produced in a printed circuit and configured to control the administration of the me drug from the administration module 10, and a power supply battery (also not visible) configured to supply power to the control unit.

[0048] The device 1 is obtained by mutually coupling the administration module 10 and the control module 20. Such coupling is reversible, that is to say that the two modules 10 and 20 can be decoupled after having been coupled.

[0049] One or more seals (not shown) are interposed between the administration module 10 and the control module 20 in order to ensure the sealing of the mutual coupling.

[0050] The administration module 10 is preferably disposable, while the control module 20 is preferably reusable. In other words, the administration module 10 is configured to be applied to the patient's body only once and for a certain period of time in order to administer the drug, completely or in part, in one or more successive injections, even if spaced apart in time. Conversely, the control module 20 can be used several times, by coupling it from time to time with a new administration module.

[0051] A cartridge (not visible) is housed in the administration module 10. The cartridge comprises a substantially cylindrical container, made of plastic or glass, containing a medication to be administered to a patient and a pierceable septum which closes the container at one of its ends and guarantees its sterility until the use of the device 1.

[0052] The administration module 10 further comprises a fluid path (also not visible) configured to be traversed by the drug during subcutaneous administration of the drug, allowing the passage of the drug from the cartridge to the patient's body. This fluid path comprises a piercing needle (not visible) configured to pierce the septum of the cartridge, an injection needle 50 (Figures 4 and 5) configured to be inserted into the patient's body and a flexible tube 51 which places the aforementioned needles in fluid communication.

[0053] The injection needle 50 is movable through the through opening 15 between a rest position in which it is entirely arranged inside the device 1, as shown in Figures 4 and 5, and an injection position (not shown) in which it projects from the device 1 through the through opening 15.

[0054] As shown in Figures 3 to 5, a protective element 60, highlighted in bold in Figures 4 and 5, is disposed around the opening 15 of the base surface 12.

[0055] The protective element 60 is movable between a first operating position in which the protective element is in an extended configuration and projects from the administration module 10 (Figures 3 and 4), possibly arranging itself even around the injection needle 50 if the latter is outside the administration module 10, and a second operating position in which the protective element 60 is in a retracted configuration and is arranged entirely inside the administration module 10 at the base surface 12 ([Fig.5]).

[0056] The protective element 60 includes a base 60a which, when the protective element 60 is in its first operative position, is located distally of the base surface 12.

[0057] In the base 60a, a through hole 62 is formed adapted to allow the passage of the injection needle 50 when the device 1 is applied to the patient's skin (and therefore when the protective element 60 is in the retracted configuration).

[0058] As shown in Figures 4 and 5, the base 60a comprises a raised edge 65 which defines in the protection element 60 a recess for housing the tip of the injection needle 50 both when the protection element 60 is in the second operating position and the injection needle 50 is in the rest position ([Fig.5]) and if the injection needle 50 is in the injection position and the protection element 60 in its first operating position.

[0059] Before applying the device 1, the protective element 60 is held in its first operating position by the pushing action exerted by an elastic element 63 which, in the embodiment illustrated here, is a compression spring.

[0060] As shown in Figures 4 and 5, the device 1 comprises a position sensor configured to signal to the control unit that the device 1 has been positioned on the patient's skin, so as to proceed with the administration of the therapy.

[0061] In particular, the position sensor comprises a magnet 71 integrally associated with the base 60a of the protection element 60 and a Hall effect sensor 72 integrally associated with the control module 20 in proximity to the magnet 71. When the device 1 is applied to the patient's skin, the protection element 60 moves inside the device 1, its base 60a moves towards the base surface 12 of the administration module 10 and the magnet 71 approaches the Hall effect sensor 72.

[0062] As shown in Figures 3 to 5, the device 1 further comprises a flexible sleeve 70 associated in a watertight manner with the base surface 12 of the administration module 10 around the through opening 15.

[0063] The flexible sleeve 70 surrounds the protective element 60 and includes a base surface 70a integrally associated with the base 60a of the protective element 60.

[0064] In the embodiment illustrated here, the flexible sleeve 70 is defined by a bellows-type membrane having a frustoconical shape.

[0065] As shown in [Fig.2], the cap 40 also has a truncated cone shape and houses with clearance the protective element 60 and the flexible sleeve 70.

[0066] The base surface 70a of the flexible sleeve 70 covers the through hole 62 of the protective element 60 and can be pierced by the injection needle 50 when the injection needle 50 moves from the rest position to the injection position.

[0067] As shown in Figures 2 and 3, a patch 30 is applied to the base surface 12 of the administration module 10.

[0068] The patch 30 comprises an adhesive layer 31 integrally attached to the base surface 12 and a protective layer 32 removably attached to the adhesive layer 31. Before carrying out the administration of the therapy, the protective layer 32 is removed and the device 1 is attached to the patient's skin through the adhesive layer 31.

[0069] The device 1 further comprises a cap 40 fixed in one piece to the protective layer 32. In particular, the cap 40 comprises a collar 35 fixed to the protective layer 32 by interposition of a double-sided adhesive element 35a.

[0070] The cap 40 is made of a rigid material and is shaped so as to completely house with clearance the protective element 60 and the flexible sleeve 70 which surrounds the protective element 60 when the latter is in its first operating position.

[0071] In the embodiment illustrated here, the cap 40 has a frustoconical shape.

[0072] As already mentioned, initially, the protective element 60 is in its extended configuration of Figures 3 and 4 and the cap 40 covers the protective element 60, as shown in [Fig.2].

[0073] Before applying the device 1 to the patient's skin, the patient removes the protective layer 32 from the patch 10, simultaneously removing the cap 40 therewith and thus releasing the protective element 60 and the adhesive layer 31 from the patch 30.

[0074] The patient can then proceed to apply the device 1 to his skin by securing the device through the adhesive layer 31 of the patch 30. The patient's skin counteracts the pushing action exerted by the elastic element 63 and causes the protective element 60 to retract inside the delivery module 10, bringing the magnet 71 closer to the Hall effect sensor 72 and thus allowing the control unit to establish that the device 1 is in contact with the patient's skin and to activate the delivery of the therapy.

Claims

Claims

1. A device (1) for subcutaneous administration of a drug, comprising: - a base surface (12) intended to face the skin of a patient when the device (1) is applied to the patient's skin and comprising a through opening (15); - a patch (30) comprising an adhesive layer (31) and a protective layer (32), wherein the adhesive layer (31) is integrally associated with the base surface (12) and is intended to be fixed to the patient's skin upon removal of the protective layer (32);- an injection needle (50) configured to inject the medicament into a patient when the device (1) is applied to the patient's skin, the injection needle (50) being movable between a rest position in which the injection needle (50) is entirely arranged within the device (1) and an injection position in which the injection needle (50) protrudes at least partially from the device (1) through said through opening (15); - a cap (40) removably associated with said base surface (12) at said through opening (15); wherein the cap (40) is integrally associated with said protective layer (32).;

2. Device (1) according to claim 1, in which the cap (40) comprises a collar (35) associated in one piece with a part of the protective layer (32) by interposition of a double-sided adhesive element (35a).

3. Device (1) according to claim 1 or 2, wherein the cap (40) is made of a rigid material.

4. Device (1) according to any one of the preceding claims, comprising - a protective element (60) arranged around said through opening (15) and movable between a first operating position in which the protective element (60) projects from the device (1) and a second operating position in which the protective element (60) does not project from the device (1); - an elastic element (63) associated with the protective element (60) and configured to exert on said protective element (60) a pushing action which is suitable for holding the protective element (60) in the first operating position before removing the protective layer (32); wherein the cap (40) is configured to accommodate the protective element (60) before removing the protective layer (32).

5. Device (1) according to claim 4, wherein the cap (40) is configured to house said protective element (60) with clearance.

6. Device (1) according to claim 4 or 5, further comprising a flexible sleeve (70) associated in a watertight manner with the device (1) around said through opening (15) and said protective element (60) and associated integrally with the protective element (60).

7. A device (1) according to claim 6, wherein the flexible sleeve (70) is defined by a bellows-type membrane and wherein the membrane and the cap (40) have a frustoconical shape.

8. Device (1) according to claim 6 or 7, wherein the protective element (60) comprises a base (60a) provided with a through hole (62) to allow the passage of the injection needle (50) during the movement of the injection needle (50) between the rest position and the injection position, and wherein the flexible sleeve (70) is associated in one piece with said base (62).

9. Device (1) according to claim 8, wherein the flexible sleeve (70) has a base surface (70a) integrally associated with the base (60a) of the protective element (60) and wherein said base surface (70a) covers said through hole (62) and can be pierced by the injection needle (50) when the injection needle (50) passes from the rest position to the injection position.

10. Device (1) according to any one of claims 4 to 9, further comprising a position sensor (71, 72) configured to detect contact of the device (1) with the patient's skin, wherein said position sensor (71, 72) comprises a magnet (71) integrally associated with the protective element (60) and a Hall effect sensor (72) arranged in the device (1) in proximity to said magnet (71).

11. Device (1) according to claim 10 when dependent on claim 8 or 9, wherein the magnet (71) is integrally associated with said base (60a).